Skip to main content
Premium Trial:

Request an Annual Quote

Mesa Laboratories Acquires Agena Bioscience for $300M

NEW YORK – Mesa Laboratories said on Tuesday that it has acquired mass spectrometry-based genetic analysis firm Agena Bioscience for $300 million in cash.

The deal is expected to close during Mesa's third fiscal quarter, which ends Dec. 31. It will be financed through a combination of cash on hand and proceeds from Mesa's credit facility, the company said in a statement.

Agena is expected to add between $63 million and $67 million to Mesa's revenues during the first year of ownership, excluding COVID-19-related revenues. Mesa, based in Lakewood, Colorado, said approximately 65 percent of that revenue is expected to be recurring and that the acquisition will likely deliver high single digit percent organic revenue growth.

San Diego-based Agena is also expected to add another $3 million to $5 million of COVID-19-related revenues during the first year of ownership, Mesa said, although the COVID-19 revenues will likely tail off significantly after that first year.

Agena received Emergency Use Authorization from the US Food and Drug Administration for its five-test SARS-CoV-2 panel in October.

"Agena brings an innovative approach to the challenges of clinical genomics," Mesa CEO Gary Owens said in a statement. "Their MassArray system is a proven platform which integrates the best of mass spectroscopy and multiplex PCR, providing a unique combination of sensitivity, cost effectiveness, fast turnaround time, ease of use, and flexibility."

"These benefits strongly address the needs of clinicians to apply patient-specific genomic information to make personalized treatment and monitoring decisions," he said.

Agena was founded in 2014 when Sequenom sold its bioscience business, with its flagship MassArray platform, for $31.8 million.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.